Published in Cancer Gene Ther on November 18, 2016
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods (1995) 16.00
Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res (2005) 5.87
Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res (2007) 5.32
DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol (2005) 5.02
Malignant mesothelioma. Lancet (2005) 3.93
Methylation matters. J Med Genet (2001) 3.00
Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol (2009) 2.17
DNA methylation and cancer. J Cell Physiol (2000) 1.89
Malignant mesothelioma in North America. Cancer (1980) 1.82
Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques (2008) 1.81
The pathogenesis of mesothelioma. Semin Oncol (2002) 1.80
Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics (2011) 1.76
Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene (2006) 1.38
Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res (1992) 1.36
LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res (2011) 1.32
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res (2009) 1.28
5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J Pharmacol Exp Ther (2004) 1.27
Azacitidine. Nat Rev Drug Discov (2005) 1.23
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol (1999) 1.13
DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer (2007) 1.11
Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun (2006) 1.08
Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer (2005) 1.06
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer (2006) 1.03
Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol (2007) 1.00
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene (2012) 0.99
Genome-wide analysis of DNA methylation in bovine placentas. BMC Genomics (2014) 0.94
Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer (2010) 0.90
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing. J Thorac Oncol (2015) 0.87
DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension. Cell (2015) 0.87
Effects of 5-aza-2'deoxycytidine on RECK gene expression and tumor invasion in salivary adenoid cystic carcinoma. Braz J Med Biol Res (2014) 0.83
Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch (2003) 0.79
Inhibition of hedgehog signaling reduces the side population in human malignant mesothelioma cell lines. Cancer Gene Ther (2015) 0.78
An Integrated Analysis of the Genome-Wide Profiles of DNA Methylation and mRNA Expression Defining the Side Population of a Human Malignant Mesothelioma Cell Line. J Cancer (2016) 0.77